公开(公告)号：US20250002945A1

公开(公告)日：2025-01-02

申请号：US18712640

申请日：2022-11-23

Applicant: CELLECTIS SA

Inventor： Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Alex BOYNE ,  Selena KAZANCIOGLU

IPC: C12N15/90 ,  C07K14/195 ,  C12N9/22

Abstract: The present invention relates to the design of improved TALE protein fusions useful as sequence-specific genomic reagents, such as TALE-nucleases and TALE base editors, displaying higher on-target/off-target activity ratios. Its goal is to produce safer reagents to genetically modify the genomes of different types of cells, especially mammalian cells, in particular for their use in gene therapy.

公开(公告)号：US20230416786A1

公开(公告)日：2023-12-28

申请号：US18253977

申请日：2021-11-30

Applicant: CELLECTIS SA

Inventor： Alexandre JUILLERAT ,  Philippe DUCHATEAU ,  Ming YANG

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/86 ,  C07D215/46 ,  C12N2750/14143

Abstract: The invention provides aminoquinoline compounds as powerful enhancers of genetic recombination in living cells, especially to perform site-directed gene integration of exogenous DNA template by homologous recombination. In particular, disclosed are methods by which cells are treated with chloroquine and/or hydroxychloroquine prior to, or concomitantly with, the introduction of exogenous DNA templates, and optionally in presence of rare-cutting endonucleases, to obtain higher rates of gene integration or correction.